Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.99 - $6.04 $71,022 - $107,512
-17,800 Reduced 93.68%
1,200 $6,000
Q1 2024

May 15, 2024

SELL
$5.3 - $7.51 $22,790 - $32,293
-4,300 Reduced 18.45%
19,000 $108,000
Q4 2023

Feb 14, 2024

SELL
$4.35 - $6.88 $16,530 - $26,144
-3,800 Reduced 14.02%
23,300 $149,000
Q3 2023

Nov 14, 2023

BUY
$4.52 - $8.9 $70,060 - $137,950
15,500 Added 133.62%
27,100 $122,000
Q2 2023

Aug 14, 2023

SELL
$4.79 - $8.3 $12,933 - $22,410
-2,700 Reduced 18.88%
11,600 $68,000
Q1 2023

May 15, 2023

SELL
$5.3 - $10.93 $5,830 - $12,023
-1,100 Reduced 7.14%
14,300 $75,000
Q4 2022

Feb 14, 2023

SELL
$4.1 - $8.94 $16,810 - $36,654
-4,100 Reduced 21.03%
15,400 $82,000
Q3 2022

Nov 14, 2022

BUY
$7.27 - $12.92 $45,074 - $80,104
6,200 Added 46.62%
19,500 $160,000

Others Institutions Holding EXAI

About Exscientia plc


  • Ticker EXAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,461,000
  • Market Cap $637M
  • Description
  • Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...
More about EXAI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.